跳至主要内容
临床试验/NCT07730424
NCT07730424已完成不适用

A Feasibility Clinical Study to Evaluate the Safety and Effectiveness of the VividWhite Glaucoma Implant (VW-50) for the Treatment of Glaucoma.

Melbourne Eye Specialists1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2022年8月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
Primary feasibility outcome

研究概览

简要总结

An investigator-initiated 10-participant Feasibility Study to assess a novel glaucoma drainage implant, VW-50.

详细描述

A single-centre, investigator-initiated device Feasibility Study where 10 participants undergo glaucoma surgery for implantation of a novel implant (VW-50) and receive 12 months of follow-up.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age - greater than 18 years of age.
  • Glaucoma - as diagnosed by the investigator based upon untreated intraocular pressure, disc appearance, and visual field abnormalities.
  • Failed medical treatment - In the opinion of the investigator, the IOP is uncontrolled in the study eye after having failed previous medical treatment.
  • Conjunctival health - In the opinion of the investigator the participant should have a healthy, free, and mobile conjunctiva in the target quadrant.
  • Capable - Ability to understand and willingness to follow study instructions and is likely to complete all required visits and procedures.

排除标准

  • Prior glaucoma surgery in the study eye.
  • Advanced glaucomatous optic nerve damage which, in the opinion of the investigator, threatens fixation and/or standard surgery would be considered safer.
  • Active neovascular glaucoma, Iridocorneal Endothelial (ICE) Syndrome, traumatic glaucoma, silicone oil induced glaucoma, active acute angle closure glaucoma or subluxation of the lens.
  • Active diabetic retinopathy, choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, proliferative retinopathy, or other ophthalmic disease or disorder in the study eye that could confound study results.
  • Any condition of the cornea that could confound study results or would preclude accurate readings with an applanation tonometer and/or a contact pachymeter.
  • Visually significant cataract in the study eye that will not be removed at the time of implantation.
  • BCVA worse than 6/30 (Snellen equivalent)
  • Clinically significant inflammation or infection in either eye
  • Unfit for local anaesthetic surgery.
  • Any uncontrolled systemic disease.
  • Female participants who are pregnant, nursing, or planning a pregnancy during the study, or who are of childbearing potential and not using a reliable means of contraception during the study.
  • Significant risk of bleeding.

结局指标

主要结局

Primary feasibility outcome

时间窗: At study intervention

Assessment of the ease of implantation of VW-50 in the human eye, measured by surgeon questionnaire assessment of implantation technique (custom 11-item questionnaire with 5 responses selectable per item, ranging from 'strongly disagree' to 'strongly agree')

次要结局

  • Secondary feasibility outcome 1(At study intervention)
  • Secondary feasibility outcome 2(12 months)
  • Safety and tolerability outcome 1(12 months)
  • Safety and tolerability outcome 2(12 months)
  • Safety and tolerability outcome 3(12 months)
  • Safety and tolerability outcome 4(12 months)
  • Efficacy outcome 1(12 months)
  • Efficacy outcome 2(12 months)

研究者

发起方
Melbourne Eye Specialists
申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验